

Available Online at http://www.recentscientific.com

CODEN: IJRSFP (USA)

International Journal of Recent Scientific Research Vol. 10, Issue, 01 (A), pp. 30218-30233, January, 2019

# International Journal of Recent Scientific Research

DOI: 10.24327/IJRSR

## **Research Article**

# INTRA/INTER SUBJECT VARIABILITY OF VARIOUS ANTI-CANCER DRUGS

Someswara Rao. K\*., PhaniBhushan Reddy.B., Srinivasu .K\*., Subba Rao.M., Vidyasagar.P and Gowri Sankar.D

AXIS Clinicals Ltd, 1-121/1, Miyapur, Hyderabad-500049

DOI: http://dx.doi.org/10.24327/ijrsr.2019.1001.3012

### ARTICLE INFO

#### Article History:

Received 12<sup>th</sup> October, 2018 Received in revised form 23<sup>rd</sup> November, 2018 Accepted 7<sup>th</sup> December, 2018 Published online 28<sup>th</sup> January, 2019

## Key Words:

Anti-cancer drugs: intra/inter-subject variability: bioequivalence

### **ABSTRACT**

Cancer is the second most common cause of death in India (after cardiovascular disease). Cancer burden in India has more than doubled over the last 26 years. Oral Cancer is among the top three cancers in India, number one among all cancers in men and number three among female cancers. Treatment of cancer is limited by affordability of patients in India. Generic drug manufacturers have responded to this scenario by making drugs available at affordable costs, often at less than 10% the cost of the original brand. Bioequivalence (BE) studies are an integral component of the development, approval and marketing of generic drug products globally and are commonly accepted method to demonstrate therapeutic equivalence between two medicinal products. Savings in time and cost are substantial when using bioequivalence as an established surrogate marker of therapeutic equivalence. For this reason the design, performance and evaluation of bioequivalence studies have received major attention from academia, the pharmaceutical industry and health authorities. Keeping in view of this, minor efforts were made to collect the intra/inter subject variability of various anti-cancer drugs, which helps in deciding the appropriate study design and sample size to establish the bioequivalence of generic drug with innovator.

Copyright © Someswara Rao. K et al, 2019, this is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

## INTRODUCTION


Cancer is the name given to an accumulation of related sicknesses. In a wide range of growth, a portion of the body's cells start to partition without ceasing and spread into encompassing tissues. Tumor can begin anyplace in the human body, which is comprised of trillions of cells. In India, there are many types of cancer treatment available. The line of cancer treatment depends on the type & stage of cancer, location of the cancerous cells, growth of the tumor, affected organs, pre-existing medical conditions of the patient, age, gender and other parameters that can only be gauged by a cancer specialist<sup>1</sup>.

Cancer is among the leading causes of death worldwide. In 2012, there were 14 million new cases and 8.2 million cancer-related deaths worldwide. The number of new cancer cases will rise to 22 million within the next two decades. More than 60% of the world's new cancer cases occur in Africa, Asia, and Central and South America; 70% of the world's cancer deaths also occur in these regions<sup>1</sup>.

In early stages of cancer, the patient can have only one form of treatment and will be cured. However, in most of the patients, a combination of treatments (from surgery, chemotherapy,


radiation therapy, hormone therapy, proton therapy, etc.) is used for cancer treatment. The cost of cancer treatment could be as low as Rupees 2.5 lakh for six months of treatment, with some of the lowest priced generic drugs in the world, to as high as Rupees20 lakh, with novel drugs and targeted medicines. The cost of lung cancer in India varies from \$10000 to \$12000, the cost of chemotherapy vary from \$250 to \$700 per session, the cost of blood cancer vary from \$20000 to \$25000,the cost of breast cancer varies from \$6,000 to \$9,000 in top hospitals in India. More than 20 tumor types are being treated with one or more of the 70 new cancer treatments that have been launched in the past five years, with the sustained surge in innovative therapies driving the global oncology market to \$107 billion in 2015. An annual global growth in the oncology drug market is expected to be 7.5 - 10.5 percent through 2020, reaching \$150 billion<sup>2</sup>. In India the following cancer statistics are identified, one woman dies of cervical cancer every 8 minutes, for every 2 women newly diagnosed with breast cancer, one woman dies of it. As many as 2,500 persons die every day due to tobacco-related diseases. Tobacco (smoked and smokeless) use accounted for 3,17,928 deaths (approx.) in men and women in 2018. Estimated number of people living with the disease are around 2.25 million. Every year, new cancer patients registered over 11,57,294 lakhs. Risk of developing cancer before the age of 75 years in males and females was found to be 9.81% 9.42% respectively. Total deaths due to cancer in 2018 are 7,84,821 lakhs, out which 4,13,519 are men and 3,71,302 are women. The risk of dying from cancer before the age of 75 years is 7.34% in males and 6.28% in females. Cancers of oral cavity and lungs account for over 25% of cancer deaths in males and cancer of breast and oral cavity account for 25% cancers in females. The top five cancers in men (lip, oral cavity, lung, stomach, colorectal and esophagus) and women (breast, lip, oral, cervix, lung and gastric) account for 47.2% of all cancers; these cancers can be prevented, screened for and/or detected early and treated at an early stage. This could significantly reduce the death rate from these cancers<sup>3</sup>.

Cancer burden in India has more than doubled over the last 26 years. Oral Cancer is among the top three cancers in India, number one among all cancers in men and number three among female cancers. Nearly 60 per cent patients with breast cancers are diagnosed in advanced stages. Breast cancer burden is not only limited to disease burden and mortality but also leads to an economic loss for the nation. India lost nearly 6.7 billion USD in 2012 due to cancer, amounting to 0.36 per cent of the total GDP. Cancer is the second most common cause of death in India (after cardiovascular disease)<sup>4</sup>.



The below mentioned picture depicts that many new oncology medicines are not available beyond the largest developed markets<sup>6</sup>.

Many new oncology medicines are not available beyond the largest developed markets



Treatment of cancer is limited by affordability of patients in many developing countries including India. Producing a generic drug will reduce the costs, often at less than 10% the cost of the original brand. In India, it is found that there is a three-fold higher prescription of generic brands compared to innovator, accompanied by cost savings of up to 80% per prescription. Unfortunately, the regulatory environment prevailing in India is not geared to ensure satisfactory quality of generic products. The standards set by the regulatory agencies for establishing equivalence of generics vis-à-vis the innovator product allow anticancer generics to enter markets without undergoing clinical evaluation. To ease the access to the cheaper and quality medicines, bioequivalence testing should be made mandatory for all oral formulations in India. Unless these measures are rigidly implemented, the benefits of generic substitution would be seriously undermined. The below emtnioend tables depicts the percentage savings from generic substitution and the prevalence of generic substitution respectively.

Name of the drug	Brand name	Cost* (INR)		%
		Innovator	Generics	savings*
Cisplatin	Platinol-AQ	\$	350-511	2
Carboplatin	Paraplatin	2,030	950-990	53.20
Oxaliplatin	Eloxatin	10,349	3420-6300	53.20
Imatinib	Glivec	12,456.00	3000-10350	75.91
Gemcitabine	Gemcite	8,622.00	5460-6201	36.67
Docetaxel	Taxotere	43,333.33	8138-10979	81.21
Rituximab	Mabethra	104,000.00	39,996	61.54
Anastrozole	Arimidex	2400.00	734.30	69.41
Bortezomib	Velcade	60,360.00	17,640	70.77
Fludarabine	Fludara	10,764.20	5,780	46.30
Gefitinib	Iressa	34,860.00	10,200	70.74
Pemetrexed	Alimta	79,050.00	25,500	67.74
Temozolamide	Temodal	34,947.00	9,450	72.95
Zolendronate	Zometa	15,213.00	2,940	80.67
Irinotecan	Camto	18,000.00	4,195	76.69

\*Cost of the drug is obtained from the hospital formulary of tata memorial hospital;
\*Percentage savings calculated based on difference in costs of the innovator and the lowest priced generic; \$Innovator not available; INR=Indian Rupees

Name of the drug	Number of brand prescription	Number of generic prescription	Total number of prescription	% of generics
Cisplatin	0	405	405	100
Carboplatin	75	206	281	73.30
Oxaliplatin	50	90	140	64.28
Imatinib	0	100	100	100
Gemcitabine	121	92	213	43.19
Docetaxel	37	15	52	28.84
Rituximab	38	23	61	37.70
Anastrozole	51	74	125	59.20
Bortezomib	10	6	16	37.50
Fludarabine	7	0	7	0.0
Gefitinib	8	50	58	86.20
Pemetrexed	16	0	16	0.0
Temozolamide	5	16	21	76.19
Zolendronic acid	21	243	264	92.04
Irinotecan	8	17	25	68.00
Total	447	1337	1784	74.94

Bioequivalence (BE) studies are an integral component of the ANDA (Abbreviated New Drug Application) approval and marketing of generic drug products.

Molecule Name Inter/Intra CV% Abiraterone Acetate 250 mg tablets Intra CV - 31% for AUC<sub>0-∞</sub>& 42% for C<sub>max</sub> Methotrexate sodium 2.5 mg tablets<sup>10</sup> Intra CV - 16.4% for  $C_{\text{max}}$ . Methotrexate sodium 50mg/2mL injectable injection<sup>11</sup> Intra CV - 24.6% for  $C_{\text{max}}$ . Brentuximab Vedotin injectable injection 50mg/vial<sup>12</sup> Intra CV - 33% Ado-trastuzumab emtansine Injection 160 mg lyophilized single use Intra CV - 15% for AUC<sub>0-∞</sub> vial (20 mg/ml afterreconstitution) for intravenous infusion 1 Intra CV of total doxorubicin – 14.05% for  $AUC_{0\infty}$  Intra CV of encapsulated Doxorubicin 14.56% for AUC $_{0-\infty}$  and 18.61% for AUC $_{49-337hr}$ . Intra  $\overrightarrow{CV}$  of free (un-Doxorubicin Hydrochloride Liposome 50mg/m2 14 encapsulated) doxorubicin – 51.52% for  $C_{\text{max},}\,32\%$  for  $AUC_{0\text{--}\infty}\,30.3\%$  for  $AUC_{0\text{--}t,}\,$ 38.40% AUC<sub>0-48</sub> and 31.57% for AUC<sub>49-337</sub> Intra CV - 22.2% to 67.5% for Ctrough.Inter CV - 57.1 to 105%. Afatinib Dimaleate 40 mg tablets15 Inter CV for  $C_{max}$  ranged from 27.6% to 31.2% and for AUCs from 32.4% to 38.7%. Everolimus 10 mg tablets16 Intra CV-17% for AUC and 19% for Cmax Alectinib 150 mg capsule17 Intra CV-18.7% for C<sub>max</sub> and 22.5% for AUC Interoccasion variability in plasma 19% and in whole blood 33%. Amifostine injectable injection 500mg/vial<sup>18</sup> Intra CV-7.8% for  $AUC_{0\text{--}\infty}$  and 7.3% for  $C_{\text{max}}$ Anastrozole 1 mg tablets<sup>1</sup> Aprepitant 125 mg capsule<sup>21</sup> Inter CV for AUC about 30% and for Cmax about 23% Asparaginase Erwinia chrysanthemi for injection, intramuscular Inter CV for CL about 14.8% and for Vd about 66.6% 10,000 IU<sup>23</sup> Atezolizumab Infusion: 60 mg/mL solution in a single use 20 mL Inter CV for CL about 29% and for Vd about 34% Inter CV for AUC about 70%, for CL about 60% and for Vd about 40%. Intra CV Axitinib 1mg and 5 mg tablets<sup>25& 58</sup> 27% Azacitidine 100mg/Vial injectable suspension<sup>26</sup> Inter CV <50%. Belinostat for injection, for intravenous 500 mg/vial<sup>27</sup> Inter CV for CL about 27% and for Vd 69%. Bendamustine Hydrochloride Injection 120 mg/m<sup>2</sup> for intravenous Residual variability 36%. Infusion<sup>28</sup> Bevacizumab (ruhMab VEGF) 400mg/vial solution for intravenous Inter CV for CL about 30.8% and for Vd 18.7%. Residual variability 12.7%. infusion30 Bexarotene 75 mg capsule31 Intra CV 40% for  $C_{\text{max}}$  and 37% for  $AUC_{\text{0--}\infty}$ Bicalutamide 50 mg tablets<sup>32&33</sup> Intra CV 13% for  $C_{max}$ , 20% for  $AUC_{0-72hr}$  and 15% for  $AUC_{0-120hr}$ Blinatumomab injectable injection 35 mcg<sup>34</sup> Inter CV for CL about 41.9% Within the observed variability (CV%) = 36-55%. Bortezomibinjectable injection 3.5 mg/Vial<sup>35</sup> High PK variability (CV%) 58 - 73% in the patient population PK model. Intra CV Bosutinib 100 and 500 mg film coated tablets36 34.2 for AUC<sub>0-t</sub> and 25.8% for  $C_{max}^{37}$ Following brigatinib 90 mg QD, the inter-subject variability (CV%) of steady-state AUC0-tau was 57% and Cmax was 65% Brigatinib 30 and 90 mg tablets38 Following brigatinib 180 mg QD, the CV% of steady-state AUC0-tau was 56% and Cmax was 60%. Intra CV - 47 % to 103 %Busulfan 2 mg tablets<sup>39</sup> Inter CV for AUC 20%. Intra-patient CV on AUC 10%. Busulfan 6mg/mL intravenous injectable Injection<sup>40</sup> Inter CV for Cl 15% . Intra-patient CV on Cl 14% Intra-patient variability of 23% for AUC<sub>0-48</sub>. Inter CV for Cl 48% and 94% for Vd. Cabazitaxel injection, for intravenous 60 mg/1.5mL (40mg/mL)<sup>41</sup> Intra CV 34% for Cmax and Cabozantinib-S-Malate Oral Capsules (20 mg and 80 mg)<sup>42</sup> 25% for AUC. Inter CV 38-61% for Cmax and 27-55% for AUC Intra CV 50.2% for Cmax and Capecitabine film-coated tablets 150, 500 mg<sup>43</sup> 22% for AUC in patients with colon, colorectal or breastcancer under fed condition with 4 x 500 mg tab dose. Intra CV for log transformed carfilzomib concentrations was 0.937. Inter CV for CL Carfilzomib powder for Intravenous injection, 60 mg/vial44 about 25% and for Vd 88% Inter CV for 42-74% for AUCinf and 35-94% for C<sub>max</sub> (single oral doses of 450 to 750 Ceritinib 150 mg capsules<sup>45</sup> mg). Inter CV in steady state AUC and  $C_{max}$  at the dose of 750 mg is 74% and 76%, respectively. Cetuximab 100mg/Vial injection for intravenous infusion 46 Inter patient CV ranged from 6 to 40%. Chlorambucil 2mg tablets The CV of AUC was 31% Cisplatin injectable injection for intravenous infusion 1mg/mL<sup>48</sup> Inter CV for Vd 27.4% and Cl 39.1%%. Cladribine injectable injection for intravenous infusion 1mg/mL<sup>49</sup> Cladribine 10 mg tablets<sup>49</sup> Inter CV 28%. CV for AUC 38% for intravenous formulation. Inter CV for AUC 36% for oral formulation Clofarabine 1 mg/mL solution for injection50 Inter CV 27% and 56%, for CL and V1 respectively. Inter CV 26% and 52%, for  $AUC_{0\text{--}\infty}$  and  $\text{ }C_{\text{max}}$  respectively in healthy subjects. Inter Cobimetinib Fumarate 20 mg tablets<sup>51</sup> CV 61% and 60%, for AUC and  $\,C_{max}$  respectively in patients at steady state. CV ranges from 36-38% and 38-44% for AUC $\tau$  and  $C_{max}$  respectively over steady state. Crizotinib 250 mg capsules<sup>52</sup> CV% values in AUCinf and Cmax range from 28% to 34% for oral administration. And 18% to 19% following intravenous infusion

53%, respectively.

Inter CV 41%, 51% and 91% for C<sub>max</sub> AUCτ and C<sub>min</sub> respectively.

Estimates of inter Occasion Variability were CL 18% and V1 21%.

Inter CV 19% to 114% for AUC $_{0-8 days}$  and from 13% to 59% for C $_{max}$ 

Inter CV 37% for  $C_{max \ ss}$  and 38% for  $AUC_{(0-\tau)}$ . Inter CV for CL/F and Vc/F is 59% and

Cyclophosphamide 50 mg capsules<sup>53</sup>

Dabrafenib mesylate capsule 75 mg<sup>55</sup>

Daratumumab Injection for intravenous infusion: 100 mg/5mL and

Cyclophosphamide 250 mg/m<sup>2</sup>

400 mg/20 mL single use vial<sup>56</sup>

IV infusion5

Dasatinib140 mg tablets<sup>57</sup>

Decitabine IV injection 50mg/vial<sup>59& 60</sup>

Defibrotide lyophilized powder, 200 mg/vial, 80 mg/mL  $\rm solution^{61,\,62\,\&\,63}$ 

Degarelix 120mg base/vial poweder for SC injection<sup>64</sup>. Denosumab 70mg/mL or 60 mg/mL subcutaneous injection<sup>65</sup> Dexamethasone 40 mg tablets

Dexrazoxane Hydrochloride 1000 mg/m<sup>2</sup> i.v. infusion<sup>67</sup>

Dinutuximab injectable injection 17.5mg/5mL 68 Docetaxel injectable injection 160mg/8mL (20mg/mL)<sup>69</sup>

Durvalumabinjectable injection 50mg/mL<sup>70</sup>

Eltrombopag Olamine 100 mg tablets<sup>71</sup>

Enzalutamide 40 mg capsule

Epirubicin Hydrochloride injectable injection 200mg/100mL  $(2mg/mL)^{2}$ 

Eribulin mesylate intravenous solution 1mg/2mL(0.5mg/mL)<sup>74</sup> Erlotinib Hydrochloride 150 mg tablets<sup>75</sup>

Etoposide 50 mg and 100 mg capsule<sup>70</sup>

Everolimus5mg and 10 mg tablets<sup>77</sup>

Everolimus tablets for oral suspension, 2mg, 3mg and 5mg<sup>78</sup>

Everolimus Tablets, 0.25 mg, 0.5 mg, and 0.75 mg<sup>79</sup>

Exemestane 25 mg tablets80

Filgrastim 300 μg/0.5 mL and 480 μg/0.8 mL single use prefilled syringe8

Filgrastim-SNDZ IV and SC injectable injection 480 mcg/0.8

Fludarabine Phosphate Injectable Injection50mg/2mL(25mg/mL)<sup>8</sup> Flutamide 125 mg capsule84

Fulvestrant intra muscular injectable injection 50 mg/mL<sup>85</sup>

Gefitinib 250 mg tablet86&87

Gemtuzumab Ozogamicininjectable injection 5mg/vial<sup>88</sup>

Goserelin Acetateimplantation implant3.6mg base<sup>89</sup> Hydroxyurea 500 mg capsules9

Ibrutinib140 mg Capsules 91& 92

Idelalisib 100 mg and 150 mg tablets93

Imatinib Mesylate 100 mg and 400 mg tablets& capsules 94& 95

Ipilimumab 50 mg/10 mL (5 mg/mL) and 200 mg/40 mL (5 mg/mL) in a single use Vial<sup>96</sup>

Irinotecan Hydrochloride 2 mL-fill vial (40mg), 5 mL-fill vial (100mg), 15 mL-fill vial (300mg) vials9

Irinotecan Hydrochloride Liposome 43 mg/10 mL single dose vial<sup>98</sup>

Ixabepilonefor intravenous Injection 15 mg/vial, 45mg/vial<sup>99</sup> Lanreotide Acetate Depot Injection 60mg base/0.2mL, 90mg base/0.3mL, 120mg base/0.5mL100 Lapatinib Ditosylate 250 mg tablets101

Lenvatinib Mesylate 10 mg capsules 103& 104

Letrozole 2.5 mg tablet105

Lenalidomide 25 mg capsules<sup>103</sup>

Leuprolide Acetate 7.5 mg SC injection<sup>106</sup> Megestrol Acetate 125mg/mLsuspension<sup>107</sup>

Melphalan 2 mg tablets<sup>108</sup> Melphalan Hydrochloride<sup>109</sup> Intra CV AUC $_{0-t}$  and  $C_{max}$  were 67.33 % and 84.44 %. Intra CV 80%.

Intra CV 31.6%. Inter CV 37% for CL and 68% for Vd.

Intra CV 25% for  $C_{max}$  and 26% for  $AUC_{0\text{--}\infty}.$  Intra CV 29.3 for  $AUC_{0\text{--}\tau}.$  Inter CV 25% for CL and 44% for Vd. Inter occasion variability 18% for CL and 20.2% for Vd. 15-20% variability observed in healthy subjects.

34-83% in patinets. CV % ranges from 20-48% for  $C_{max}$  and AUC.

and residula variability high and low concentrations are 26 and 81% respectively. Intra CV 12% for C<sub>max</sub>.

Intra CV 13.6%, 14.9% and 38.0% for CL, AUC and Vd respectively. Inter CV

30.4%, and 35.6% for CL and Vd respectively. Inter CV 62% for CL and 36% for Vd.

Intra CV 44.3% for C<sub>max</sub> and 48% for AUC<sub>0-t</sub>.

Inter CV 29.3%, 21.2%, and

39.9% for CL, V1, and V2 respectively.

Inter CV 30%, and 40% for AUC and C<sub>max</sub> respectively.

Inter CV for AUC and  $C_{max} \le 31\%$  respectively.

Inter CV 53.3%, and 44% for CL, and Vd respectively.

Inter CV 54% for CL.

Intra CV 30% for  $C_{max}$  and 29.6 for  $AUC_{0-t}$ .

Inter-patient variability of AUC 25% for the IV route and 35% after oral intake. Inter CV for C<sub>max</sub> ranged from 27.6% to 31.2% and for AUCs from 32.4% to 38.7%. Intra CV%

17% for AUC and 19% for  $C_{\text{max}}.$  Inter CV 51.2% for  $C_{\text{max}}$  and 36.0% for  $AUC_{0\text{--}\tau}$  in patients with renal cell carcinoma at steady-state.

Intra CV 22.4 % for AUC and 20.2% for  $C_{max}$ .

Intra CV% 44 %, 26% and 24% for  $C_{min}$ ,  $C_{max}$  and  $AUC_{0-\tau}$  respectively in De Novo Kidney Transplant patients. Intra CV% 38 %, 30% and 30% for  $C_{min}$ ,  $C_{max}$  and  $AUC_{0-\tau}$ respectively in De Novo Heart Transplant patients.

Intra CV 40.25%, 40.47% and 40.25% for  $^1C_{max}$ , AUC $_{0-t}$  and AUC $_{0-\omega}$  respectively. Variability (% CV for  $C_{max}$  and AUC) 5µg/kg SC dosing in helathy subjects 40%, breast cancer 35%, lung cancer 60% and non-Hodgkin's Lymphoma 23%.

Inter CV 40% in patients and 20% in healthy subjects.

Residual unexplained variability is 22.36%

Inter CV 22-51% in patients with renal insufficiency

Inter CV 25 and 70% for AUC<sub>0-28d</sub>and between 28 and 83% for C<sub>max</sub>, steady state, CV% about 15%

Inter CV for AUC was 66-

67% and for Cmax was 52-55%.

Intra CV 17-30%

Inter-subject CV was very large: %CV was 62% and 136% for C<sub>max</sub> and AUC of hP67.6 (antibody)

Intra CV 30.9 % for AUC $_{0-\infty}$  and 14.4% for  $C_{max}$ in helathy young women Intra CV 3.0 % for AUC $_{0-\infty}$  and 16.5% for  $C_{max}$  in healthy subjects.

Intra CV were approximately 61% for C<sub>max</sub> and 47% for AUCs of

ibrutinib. Inter CV % ranged from

58.5% to 136% for  $C_{max}$  and 60.1% to 107% for  $AUC_{0.24h}$  Intra CV 53%. Inter CV for CL/F to be 38% and in Vc/F to be 85%.

Intra CV 13.6%, 12.8% and 12.3% for  $C_{max}$ ,  $AUC_{0-t}$  and  $AUC_{0-\infty}$  respectively.

18.2%, 11.6% and 11.8% for  $C_{max}$ ,  $AUC_{0-t}$  and  $AUC_{0-\infty}$  respectively.

Inter CV 39.5% for CL and 22.9% for Vd.

Inter CV 13.5% for CL and 37.9% for AUC.

Inter CV 77%, 49% and 88% for AUC<sub>0-∞</sub>, Vd, and CL respectively.

The variability in PK parameters ranged from 47-55%.

PK: Inter CV 19%, and 44% for CL and Ka respectively

PD: EC50, E0 and Emax is 43%, 85% and 14% respectively.

Overall variability ranges from 39 to 79%, for Cmax, from 31 to 90% for AUC.

Intra CV% 9% and 18% for  $C_{max}$ , and  $AUC_{0-t}$ 

Inter CV 36%, and 78% for Cycle 1, Day 1, Cmax and AUC<sub>0</sub>-τ respectively.

Inter CV 19%, and 54% for Cycle 2, Day 1, Cmax and  $AUC_0\text{-}\tau$  respectively. Inter CV 25.5% for CL.

%CV of AUC in helathy subjects ranged from about 8% to 20%.

Intra CV% 14% and 6% for  $C_{max}$ , and  $AUC_{0-\infty}$ 

Inter CV 24.7% in AUC<sub>0-tldc</sub>

Intra CV% 21.4%, 19.7% and 41% for  $C_{max}$ ,  $AUC_{0-t}$  and  $AUC_{0-\infty}$  respectively. Total melphalan Inter CV 59.5% and 33.6% for Vd, and CL respectively. Unbound melphalan Inter CV 57.2% and 41.7% for Vd, and CL respectively.

Inter CV 37% and 21% for Vd, and CL respectively

Mercaptopurine 50 mg tablets<sup>110</sup>

Mercaptopurine 20 mg/mL oral suspension<sup>110</sup>

Mesna 400 mg tablets<sup>11</sup>

Methylnaltrexone Bromide 150 mg tablets<sup>112</sup>

Methylnaltrexone Bromide 12mg/0.6mL SC injection<sup>113</sup>

Midostaurin 25 mg capsules<sup>114</sup>

Necitumumab IV injection 800 mg/50 mL (16 mg/mL) vial<sup>115</sup>.

Nelarabine IV injection 250mg/50mL (5mg/mL)<sup>116</sup>

Netupitant 300 mg and Palonosetron Hydrochloride 0.5 mg capsule<sup>117</sup>

Fosnetupitant chloride hydrochloride 235 mg; Palonosetron hydrochloride 0.5 mg IV injection<sup>11</sup>

Nilotinib 200 mg capsules118

Niraparib Tosylate Monohydrate 100 mg capsule<sup>119</sup>

Nivolumab 40 mg/4 mL injectable injection single-use vial<sup>120</sup>

Obinutuzumab intravenous injection for infusion 1000 mg/40mL (25 mg/mL) single use vial121

Ofatumumab intravenous injection 100 mg/5 mL and 1000 mg/50 mL single-use vial<sup>12</sup>

Olaparib 50 mg capsule<sup>123</sup>

Olaparib 150 mg tablets 124

Olaratumab injectable injection 500mg/50mL<sup>125</sup>

Omacetaxine Mepesuccinate3.5mg/vial SC injection 126

Osimertinib 40 mg and 80 mg tablets 127

Pcalitaxel Protein-Bound (albumin-bound) Particles Injectable Suspension 100mg/vial 128

Palbociclib Capsules: 125 mg, 100 mg, and 75 mg<sup>129</sup>

Palifermin injectable injection 60mcg/kg/day<sup>130</sup>

Palonosetron HydrochlorideIV injection 0.25 mg/5 mL<sup>131</sup>

Panitumumab 5ml/100mg, 10ml/200mg 20ml/400mg vials (20 mg/mL) injectable injection<sup>132</sup>.

Panobinostat 10 mg, 15 mg 20 mg capsules<sup>133</sup>

Pazopanib Hydrochloride 200 mg, 400 mg tablets 134, 135& 136

Pegaspargase solution for injection or infusion 750 U/mL<sup>137</sup>.

Peginterferon Alfa-2a<sup>138</sup>

Peginterferon Alfa-2b<sup>139</sup>

Pembrolizumab 50mg IV injection 140

Pemetrexed Disodium for injection 500mg base/vial<sup>141</sup>

Pertuzumab 420mg/14ml single use vial<sup>1</sup>

Plerixafor 24mg/1.2ml (20mg/ml) subcutaneous Solution for  $Injection^{143} \\$ 

Pomalidomide 4 mg capsules<sup>144</sup>

Pralatrexate 20mg/ml (20mg/ml) and 40mg/2ml (20mg/ml) IV injection145

Raloxifene Hydrochloride 60 mg tablets<sup>146</sup>

Regorafenib 40 mg tablets<sup>147</sup>

Ribociclib succinate 200 mg tablets<sup>148</sup>

Rolapitant Hydrochloride 90 mg tablets and injection 149

Romidepsin injection for intravenous infusion 10mg/vial<sup>150</sup>

Rucaparib Camsylate Tablets: 200 mg and 300 mg151

Ruxolitinib Phosphate Tablets: 5 mg, 10 mg, 15 mg, 20 mg and 25 mg<sup>152</sup>

Inter CV 68.8% 39.5% and 38.5 for  $C_{max}$ ,  $AUC_{0\text{-t}}$  and  $AUC_{0\text{--}\infty}$  respectively.

Inter CV 45.8% 30.1% and 30.1 for  $C_{max}$ ,  $AUC_{0-t}$  and  $AUC_{0-\infty}$  respectively. Inter CV 34% and 23% for  $C_{max}$  and  $AUC_{0-t}$  respectively.

Inter CV 55-85% for C<sub>max</sub> and AUC 27%-56% respectively.

Inter CV 30% for C<sub>max</sub> and AUC 20% respectively

Intra and inter CV 61% and 61% respectively for 50 mg BID and Intra and inter CV 32% and 54% for 100 mg BID.

Inter CV ranged from 21% to 55% for Vd and 25.5%-31.9% for CL.

Inter CV ranged from 42-115% for Nelarabine, 20-39% for deoxyguanosine analogue 9-β-Darabinofuranosylguanine (ara-G) and 87-93% for for deoxyguanosine analogue 9-β-

Darabinofuranosylguanine 5-triphosphate (ara-GTP).

Inter %CV ranges from 25-60% in for netupitant for helathy subjects.

Fed:Intra CV% 30.9%, 19.4% and 20.1% for C<sub>max</sub>, AUC<sub>0-t</sub> and AUC<sub>0-∞</sub> respectively for netupitant and

Fed:Intra CV% 12.0%, 10.0% and 9.0% for C<sub>max</sub>, AUC<sub>0-t</sub> and AUC<sub>0-∞</sub> respectively for Palonosetron.

The CVs of about 37%, 23%, and 32% for the netupitant 50 mg, 75 mg and 100 mg doses, respectively for netupitant.

Inter CV in patients ranges from 30-70% for C<sub>max</sub> and AUC, in healthy subjects inter CV ranges from 30-50% for C<sub>max</sub> and AUC.

The inter CV% for CL and Vd 38.7% to 103%.

The inter CV% for CL and Vd 50% and 30.4% respectively.

Inter patient variability for AUC<sub>7d</sub> rages from 28 to 144% and for Cmax: 21 to 74%.

The inter CV% for Vd 6% and CL 31%.

High PK variability: Single dose 65% and for multiple dose 74%.

The inter CV% for CL-45%, V1-70% and V2-73% at steady state.

The inter CV% for CL-38.2% and V1-22.2%.

Inter CV% for AUC is 70%.

Inter CV% for Cycle 1, Day 1, C<sub>max</sub> and AUC<sub>0-τ</sub> ranges from 36% to 78% and for Cycle 2, Day 1,  $C_{max}$  and  $AUC_{0\mbox{-}\tau} ranges$  from ~19% to 54 %.

Intra CV in breast cancer patients it is 21.3% for total paclitaxel and unbound paclitaxel.

Fasting: Inter CV is 39% for AUCinf and 73% for Cmax; Fed: Inter CV is 23% to 27% for AUCinf and 21% to 24% for Cmax

The inter CV% for CL-40% and Vd-70%.

The inter CV% for CL-88.8% and Vd-35.8%.

The inter CV% for CL-54% and Vd-25%.

Intra CV for Cmax-52% and AUC0-inf-38% in patients with oral administration. Intra CV for Cmax-34% and AUC0-inf-17% in patients with IV administration. The inter CV% for CL-65%

The mean intra-patient CV in AUC<sub>0-24</sub>was 24.7% (range, 8.3 - 48.7%). The inter CV% for CL-52.3 and for Vd-67.1%. Intrapatient CV in PK (25-27%).

Inter-patient CV for AUC: between 22.2% and 120.2% and for Cmax: between 19.7% and 62.1%

Variability in PK parameters ranges from 50-80%

Inter-patient CV for AUC:36.8%

The inter CV% for CL and Vd 28.1% and 13.5% respectively.

The inter CV% for CL, V1 and V2 25.8%, 13.5% and 26.0% respectively.

Inter CV of CL and Vd are 34.9% and 18.7%, respectively.

PK variability in different cancer types ranged between 14-24%. For healthy volunteers the CV% for Cmax and AUC ranged from 11-16%.

Inter CV for AUC was between 13.5% to 39.4% in healthy subjects and 20.5% to 55.4% in multiple myeloma patients, respectively. Intra CV for AUC ~10% in healthy subjects. Intra CV for C<sub>max</sub> ranged from 11.3% to 26.2% and 11.1% to 40.6% in healthy subjects and multiple myeloma patients, respectively

PK inter CV >50%.

Intra CV ~30%

Intra CV for  $C_{max,ss}$  is 32% and  $AUC_{0\text{-}24hrs,ss}$  is 34%. Inter CV for  $C_{max}$  is 44% and AUC is 35% in solid tumor patients. Inter CV in solid tumor patients Cmax,ss is 44% and AUC<sub>0-24hrs,ss</sub> is 43%. Iner CV in metastatic colorectal cancer for  $C_{max,ss}$  is 63% and  $AUC_{0.24hrs,ss}$  is 86%. In patients with cancer after 600 mg multiple doses, CV% for C<sub>max</sub>: 66.0 % and AUC<sub>0-24</sub>:

The variability in exposure (Cmax and AUC) was low to moderate with coefficients of variation ranging from 10% to 47%.

Intra CV in refractory neoplasm patients for Cmax and AUC ranges from 30-80%. Inter CV in T cell lymphoma patients ranges from 50 to 70%.

CVs of C<sub>max ss</sub> and AUC<sub>0-12SS</sub> ranged from 43% to 72% and 58% to 73%, respectively.

Fed: CVs of C<sub>max</sub> ss and AUC<sub>0-12SS</sub> ranged from 73% to 84% and 74% to 76%,respectively. In healthy volunteers inter CV%, ranging from 19.0% (200 mg) to 55.9% (25 mg) for  $C_{max}$  and from 8.59% (200 mg) to 34.0% (25 mg) for AUC  $_{0\!-\!\infty}$  21.7 to 35.8% for  $C_{max\;ss}$  and from 27.0 to 31.3% for C  $_{max\;ss}$  $AUC_{0-\tau ss}$  at steady state. In myelofibrosis patients, the inter CV%, ranging from 2.2-44.1% for ruxolitinib

and from 20-57% for AUC<sub>0-7</sub>

Siltuximab Injection for Intravenous infusion 100 mg & 400 mg of lyophilized powder in a single-use vial  $^{153}$ 

Sonidegib Phosphate 200 mg capsules<sup>154</sup> Sorafenib Tosylate tablets 200 mg<sup>1</sup>

Sunitinib Malate Capsules 12.5 mg, 25 mg and 50 mg capsules 156

Tamoxifen Citrate 40 capsules and tablets<sup>157</sup>

Temozolomide 250 mg capsules 158& 159

Temsirolimus injection for intravenous infusion 25 mg/mL<sup>160</sup>

Thalidomide50mg Hard Capsules<sup>161</sup>

Thioguanine 40 mg tablets<sup>162</sup>

Thiotepa for injection,

15 mg and 100 mg lyophilized white powder in single-dose vial forreconstitution1

Topotecan Hydrochloride 0.25 mg and 1 mg capsules and 4mg base/vial IV injection<sup>16</sup>

Toremifene 40 mg tablets165

Trabectedin IV injection 1 mg sterile lyophilized powder in a singledose vial10

TrametinibTablets 0.5 mg, 1 mg, and 2 mg<sup>167</sup>.

Uridine Triacetate 10gm/packet oral granules 168

Vandetanib 100 mg and 300 mg tablets 169

Vemurafenib 240 mg tablets<sup>170</sup>

VenetoclaxTablets 10 mg, 50 mg, 100 mg<sup>171</sup> Vincristine sulfate liposome injection for intravenous Infusion 5mg/5ml (1mg/ml)<sup>1</sup>

Vismodegib 150 mg capsule<sup>173</sup>

Vorinostat 100 mg capsule174

Ziv-Aflibercept 25 mg/mL solution for IV infusion<sup>175</sup>

Aldesleukin (Interleukin-2)176

Alemtuzumab IV injection $30\ mg/1\ mL$  single use vial  $^{177}$ 

Avelumab IV injection weight-based (10 mg/kg Q2W) and flat (800 mg Q2W) dosing regimen1

Carboplatin Aqueous Solution Injection 50mg, 150 mg, and 450 mg and carboplatin 50 mg/m<sup>2</sup>

/day i.v<sup>179& 180</sup>

Cytarabine Liposome injection 10mg/mL181

Daunorubicin Hydrochloride injectable injection 5mg<sup>181</sup> base/mL

Elotuzumab 400 mg injectable injection<sup>1</sup>

5-Aminolevulinic acid hydrochloride crystalline powder for oral solution 30mg/mL183

Lomustine 100 mg capsules<sup>183</sup>

Vinorelbine Ditartrate capsules 20 mg and 30 mg<sup>183</sup> Procarbazine Hydrochloride 50 mg capsules<sup>18</sup>

Nilutamide 150 mg tablet<sup>184</sup>

Rituximab Hydrochloride 10 mg/vial<sup>185</sup>

Zoledronic Acid for Injection Concentrate4 mg/5 mL zoledronic acid (as zoledronic acid monohydrate)18

Ramucirumab 500mg/50mL injectable injection<sup>187</sup>

Rasburicase<sup>188</sup>

Pegfilgrastim subcutaneous Injection: 6 mg/0.6 mL solution in a single-dose prefilled syringe<sup>189</sup>

Single-dose intersubject variability in AUC<sub>0-inf</sub> and C<sub>max</sub> were 39% and 27% (%CV), respectively. Multiple-dose (Day 43)intersubject variability in AUC<sub>0-t</sub> and C<sub>max</sub> were 39% and 30% (%CV), respectively.

Inter CV of CL and Vd are 67% and 213%, respectively.

Inter CV in pharmacokinetics ranges from 36% to 91%.

Variability in PK parameters in healthy subjects ranges from 15-36% for C<sub>max</sub> and AUC and in patients ranges from 25-60% for C<sub>max</sub> and AUC.

Intra CV% 10.3%, 7.4% and 12.5% for  $C_{max}$ ,  $AUC_{0-72}$  and  $AUC_{0-\infty}$  respectively.

Intra CV% 17.7%, 12.9% and 12.2% for  $C_{max}$ ,  $AUC_{0-t}$ &  $AUC_{0-\infty}$  respectively. The intersubject variability in clearance was 15%, and the residual variability was 26%

PK Variability in cancenr patients ranges from 20-40% and in helathy subjects ranges from 2-20% for C<sub>max</sub> and AUC

Coefficients of variation (CV%) for AUC<sub>(0-∞)</sub> and C<sub>max</sub> were low suggesting a low interindividual variability.

Intra CV% 71.3% and 56.1% for C<sub>max</sub> and AUC<sub>0-t</sub>respectively.

CV% for  $C_{max}$ : 6-74% and  $AUC_{0-t}$ : 10-25% (Thiotepa). CV% for C<sub>max</sub>: 8-19% and AUC<sub>0-t</sub>: 11-22% (TEPA).

Intra CV% 43% for oral administration and 22.5% after IV administration.

Intra CV% 8.3% for AUC and inter CV% 25.3 for AUC.

The inter and intra CV in clearance of trabectedin were 50% and 31%, respectively in patients with cancer

Inter-patient variability at steady state (on day 15) is 22% in AUC and 28% in C<sub>max.</sub> Inter CV of CL and Vd are 24% and 77%, respectively.

The inter-CV of uridine concentrations ranged from 44% to 65% for 10 gram dose. In healthy subjects inter CV% for AUC and Cmax ranged from 8.4% to 25.8%. Intra CV% within 20% for AUC and within 10% for Cmax. In patients inter CV% of 40% to 77% for Cmax and 57.44% to 175.9% % for AUC at a single dose, and 60.7% for Cmax and 58.4% for AUC at Day 29.

The inter-subject variability was relatively small at 37% for C<sub>max</sub> and 32% for AUC<sub>0-8h</sub> on Day 15 at the 960 mg bid dose. Inter CV of CL and Vd are 31.9% and 65.7%, respectively. Inter CV of CL and Vd are 40.7% and 47.7%, respectively.

Inter CV for  $C_{max},\,AUC_{0\text{--}t},\,AUC_{0\text{--}\infty}$  and CL are 18.8%, 41.3%, 43.7% and 51% respectively.

The inter for CV% CL and Vdwas 49% and 46%, respectively. Intra CV% for total and unbound concentrations was 27% and 42%, respectively.

The variability in AUC<sub>0-∞</sub> and C<sub>max</sub> ranges from 35-54%.

The inter CV% for CL and Vd was 28% and 20%, respectively.

The variability in AUC  $_{\!0\!-\!\infty}$  and  $C_{max}$  ranges from 15.23-62.21% and -23.9%-66.42% respectively.

The inter CV alemtuzumab pharmacokinetics was large (>30% for all PK parameters). Inter CV for V1 and V2 was 84% and 179%, respectively.

The overall variability 27.1% vs 29.0% for AUC<sub>0-336h</sub>; 38.6% vs 41.2% for AUCss forweight-based (10 mg/kg Q2W) and flat (800 mg Q2W) dosing regimen.

Inter-patient variability in PK pharmacokinetics ranges from 15% to 21%. Interpatient variability for AUC<sub>0-∞</sub> is 68.6%. Intrapatient variability for CLis 40%.

Inter-subject variability was 52% for CL and 117% for liposomal Vd for cytarabine Inter-subject variability was 44% for CL and 146% for liposomal Vd for daunorubicin. Inter-subject variability was 31.6% for CL, 20.3% for V1 and 34.6% for V2.

Inter CV 4-13%.

Inter CV 51-62%%.

Intra CV 19% and inter CV 20%.

Inter CV 38-106%.

Oral bioavailability 97%. Low intra CV is expected

The inter-patient variability for CL, V1 and  $\dot{V}2$  was 29.3%

(estimation of CV = 4.74%), 10.7% (estimation of CV = 14.0%), and 22.5% (estimation of

15.3%) respectively

Inter-patient variability of clearance was 36%.

The inter-patient variability for CL, V1 and V2 was 32.3%, 22.9% and 54.0% respectively. Total patient variability in Ceoi and AUC<sub>0-24</sub> was 21.8 and 42.6%, respectively.

The inter-patient variability for CL, Vd was 50.5% and 53.1% respectively.

V1=Central volume of distribution, V2=Pheripheral volume of distribution, CL= Clearance, Vd: volume of distribution; PK: Pharacokinetics, Ceoi=Plasma concentration observed at the end of IV infusion.

BE studies are generally designed to determine if there is a significant difference in the rate and extent to which the active drug ingredient, or active moiety, becomes available at the site of drug action.

According to the criteria developed by the U.S. (United States) Food and Drug Administration (FDA) and generally applied by other regulatory agencies, two pharmaceutically equivalent products are judged bioequivalent if the 90% confidence

interval of the geometric mean ratio (GMR) of AUC and  $C_{max}$  fall within  $80.00\text{-}125\%.00^8$ .

An effort an was made to compile the data of inter/intra-subject varibaility of various anti-cancer drugs for ready reference in order to determine the appropriate study design and sample size, which is an important component to determine the cost of the bioequivalence studies while conducting the pivotal stuides, which in turn may help in producing more generic anti-cancer durgs globally including in India.

## References

- Center for Cancer Research, National Cancer Institute Building 31, Room 3A1131 Center Drive, Bethesda, Maryland 20892.
- https://www.quora.com/Approximately-what-is-theoverall-cost-of-cancer-treatments-in-India-I-am-goingto-take-critical-illness-health-insurance-and-want-toknow-how-much-coverage-I-should-take-Is-16-lakhreally-enough-in-case-of-cancer-any-type-except-skin.
- Cancer Statistics. http://cancerindia.org.in/cancerstatistics/
- 4. Oncology Drugs Market Asia, India, China and Japan. http://www.news.kenresearch.com/post/121342831908/india-china-oncology-drugs-market-report.
- 5. A to Z List of Cancer Drugs, https://www.cancer.gov/about-cancer/treatment/drugs
- IMS Institute for HealthCare Informatics. "Global Oncology Trend Report. A Review of 2015 and Outlook to 2020". http://phrma-docs.phrma.org/sites/default/ files/pdf/cancer\_chart\_pack.pdf
- 7. Toward better quality of anticancer generics in India, http://www.indianjcancer.com/temp/IndianJournalofCancer513366-5064275 140402.pdf.
- 8. U.S. Food and Drug Administration. Guidance for Industry: Bioavailability and Bioequivalence Studies.
- 9. Center for drug evaluation and research, application number: 202379Orig1s000, Clinical Pharmacology Reviewhttps://www.accessdata.fda.gov/drugsatfda\_docs/nda/2011/202379Orig1s000ClinPharmR.pdf
- Center for drug evaluation and research, Approval Package for: application number: ANDA 40-385; Trexall tablets (Methotrexate tablets, USP) https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 01/040385\_S000\_TREXALL%20TABLETS%20\_ORI GINAL.pdf
- 11. Clinical pharmacology review for methotrexate injection, NDA 204824. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/2013/204824Orig1s000ClinPh armR.pdf
- 12. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 11/125388Orig1s000ClinPharmR.pdf.
- 13. Pharmacokinetic Bioequivalence, Safety, and Immunogenicity of DMB-3111, a Trastuzumab Biosimilar, and Trastuzumab in Healthy Japanese Adult Males: Results of a Randomized Trial, BioDrugs (2016) 30:17-25,
  - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC474621 4/pdf/40259\_2015\_Article\_153.pdf
- 14. Committee for Medicinal Products for Human Use (CHMP). CHMP assessment report. Doxorubicin SUN. European Medicines Agency EMA/588790/2011. 2011.

- http://www.ema.europa.eu/docs/en\_GB/document\_librar y/Application\_withdrawal\_assessment\_report/human/00 2049/WC500112957.pdf
- Center for drug evaluation and Research, Application Number: 201292Orig1s000, clinical pharmacology and biopharmaceutics review(s). https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 13/201292Orig1s000ClinPharmR.pdf
- Center for drug evaluation and research, application number: 22-334, Clinical Pharmacology Review. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 09/022334s000 ClinPharmR.pdf
- 17. Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapy, Cancer Sci 107 (2016) 1642-1646.http://onlinelibrary.wiley.com/doi/10.1111/cas.13066/pdf
- 18. Clin Cancer Res. 2010 February 1; 16(3): 1049. doi:10.1158/1078-0432.CCR-09-1997, Clinical Pharmacokinetics of Amifostine and WR1065 in Pediatric Patients with Medulloblastoma https://www.ncbi.nlm.nih.gov/pmc/articles/PMC281867 5/pdf/nihms-164214.pdf.
- Anastrozole 1 mg film coated tablets, PL 187227/0014, UKPAR. http://www.mhra.gov.uk/home/groups/par/documents/w ebsiteresources/con093709.pdf
- 20. Nanomedicine of anastrozole for breast cancer: Physicochemical evaluation, in vitro cytotoxicity on BT-549 and MCF-7 cell lines and preclinical study on rat model.
  - https://www.researchgate.net/publication/282361229\_N anomedicine\_of\_anastrozole\_for\_breast\_cancer\_Physico chemical\_evaluation\_in\_vitro\_cytotoxicity\_on\_BT-549\_and\_MCF-
- 7\_cell\_lines\_and\_preclinical\_study\_on\_rat\_model
  21. Scientific Discussion;
- http://www.ema.europa.eu/docs/en\_GB/document\_librar y/EPAR\_-\_Scientific\_Discussion/human/000527/WC500026534.p
- df

  22. Evaluation of particle size reduction on dissolution and oral bioavailability of aprepitant. https://doi.org/10.1016/j.nano.2015.12.162
- Assessment report, Spectrila, International non-proprietary name: Asparaginase, Procedure No. EMEA/H/C/002661/0000, 26 November 2015, EMA/CHMP/842555/2015, Committee for Medicinal Products for Human Use (CHMP).
- 24. http://www.ema.europa.eu/docs/en\_GB/document\_librar y/EPAR\_\_Public\_assessment\_report/human/002661/WC5002005
  40.pdf
- Center for Drug Evaluation and Research, Application number: 761034Orig1s000, clinical pharmacology and biopharmaceutics review(s). https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 16/761034Orig1s000ClinPharmR.pdf
- 26. Center for Drug Evaluation and Research, Application number: 202324orig1s000, Clinical pharmacology and Biopharmaceutics review(s).

- https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 12/202324Orig1s000ClinPharmR.pdf.
- 27. Center for Drug Evaluation and Research, Approval Package for: Application number: 50-793, Clinical pharmacology and Biopharmaceutics review. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 04/50-794 Vidaza BioPharmr.pdf.
- 28. Center for Drug Evaluation and Research, Application number: 206256Orig1s000, Clinical pharmacology and Biopharmaceutics review(s).
- 29. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 14/206256Orig1s000ClinPharmR.pdf.
- 30. J. S. Owen<sup>1</sup>, M. Melhem<sup>1</sup>, D. D'Andrea<sup>2</sup>, M. Darwish<sup>2</sup>
  Population Pharmacokinetics of Bendamustine and Metabolites in Patients with Indolent Non-Hodgkin Lymphoma 1. Cognigen Corporation, Buffalo, NY; 2. Cephalon, Inc., Frazer, PA. http://www.cognigencorp.com/images/uploads/posters/poster78\_ascpt\_poster\_2008mar06.pdf
- 31. Int. J. Pharm. Sci. Rev. Res., 23(2), Nov Dec 2013; n° 16, 89-93, Formulation and Evaluation of Stable Lyophilized Bendamustine Hydrochloride Injection.
- 32. Center for Drug Evaluation and Research, Approval Package for: Application number: STN-125085/0, Clinical pharmacology /TOX Review.https://www.accessdata.fda.gov/drugsatfda\_docs/nda/2004/STN-125085\_Avastin\_BioPharmr.pdf.
- 33. Targretin: EPAR Scientific Discussion, http://www.ema.europa.eu/docs/en\_GB/document\_librar y/EPAR\_\_\_Scientific\_Discussion/human/000326/WC500034204.p
- 34. PAR bicalutamide 50 mg and 150 mg film coated tablets, procedure no: UK/H/5813/001-2/DC, UK license number PL17907/0503-0504, Bristol Laboratories Ltd. http://www.mhra.gov.uk/home/groups/par/documents/w ebsiteresources/con594413.pdf
- 35. Suhas Sahebrao Khandave\*, Shahoo Vasant Onkar, Satish Vitthal Sawant and Santosh Shrikrishna Joshi, J Bioequiv Availab ISSN:0975-0851 JBB, an open access journal Volume 2(4): 077-080 (2010) 077, Evaluation of Performance of the Truncated Area Under Curve (AUC) as a Primary Pharmacokinetic Parameter in Bioequivalence Studies.
- 36. Center for Drug Evaluation and Research, Approval Application number: 125557Orig1s000, clinical pharmacology and biopharmaceutics review(s). https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 14/125557Orig1s000ClinPharmRedt.pdf.
- 37. AusPAR Velcade Bortezomib Janssen-Cilag Pty Ltd PM-2011-00854-3-4, Final 16 January 2013.
- 38. Center for Drug Evaluation and Research, Approval Application number: 203341Orig1s000, clinical pharmacology and biopharmaceutics review(s). https://www.accessdata.fda.gov/drugsatfda\_docs/nda/2012/203341Orig1s000ClinPharmR.pdf.
- 39. Vargas M, Villarraga EA (2016) Bioequivalence Study of Two Formulations Containing Bosutinib 500 mg Tablets in Healthy Colombian Volunteers. J Bioequiv Availab 9: 299-301. doi: 10.4172/jbb.1000314.

- 40. https://www.omicsonline.org/open-access/bioequivalence-study-of-two-formulations-containing-bosutinib-500-mg-tablets-in-healthy-colombian-volunteers-jbb-1000314.pdf
- 41. NDA 208772 Multidisciplinary Review and Evaluation ALUNBRIG (brigatinib). https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 17/208772Orig1s000MultidisciplineR.pdf
- 42. Summary of Product Characteristics Updated 02-Mar-2016 | Aspen. Busulfan 2 mg tablets. https://www.medicines.org.uk/emc/printdocument?documentId=24686
- 43. Scientific Discussion.Busilvex, INN-Busulfan European Medicines Agency.
- 44. http://www.ema.europa.eu/docs/en\_GB/document\_librar y/EPAR\_-\_Scientific\_Discussion/human/000472/WC500052062.p df
- 45. Center for Drug Evaluation and Research, Approval Application number: 201023, clinical pharmacology and biopharmaceutics review(s). https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 10/201023s000ClinPharmR.pdf.
- 46. Center for Drug Evaluation and Research, Approval Application number: 203756Orig1s000, clinical pharmacology and biopharmaceutics review(s). https://www.accessdata.fda.gov/drugsatfda\_docs/nda/2012/203756Orig1s000ClinPharmR.pdf.
- 47. Capecitabine film-coated tablets 150 and 500 mg, PL 20117/0207, PL 20117/0208, UKPAR. http://www.mhra.gov.uk/home/groups/par/documents/w ebsiteresources/con418514.pdf.
- 48. Center for Drug Evaluation and Research, Approval Application number: 202714Orig1s000, clinical pharmacology and biopharmaceutics review(s). https://www.accessdata.fda.gov/drugsatfda\_docs/nda/2012/202714Orig1s000ClinPharmR.pdf.
- 49. Center for Drug Evaluation and Research, Approval Application number: 205755Orig1s000, clinical pharmacology and biopharmaceutics review(s). https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 14/205755Orig1s000ClinPharmR.pdf.
- 50. Center for Drug Evaluation and Research, Approval Application number: STN/BLA 125084, clinical pharmacology and biopharmaceutics review(s).https://www.accessdata.fda.gov/drugsatfda\_docs/bla/2004/125084\_ERBITUX\_BIOPHARMR.PDF.
- 51. Raija Silvennoinen, Kimmo Malminiemi , Outi Malminiemi , Erkki Seppala and Juhani Vilpo., Pharmacokinetics of Chlorambucil in Patients with Chronic Lymphocytic Leukaemia: Comparison of Different Days, Cycles and Doses; Pharmacology & Toxicology 2000, 87, 223-228.
- 52. Sail Urien & François Lokiec: Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Br J Clin Pharmacol 57:6 756-763. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC188452 6/pdf/bcp0057-0756.pdf
- 53. Jan H. M. Schellens, Howard L. McLeod, David R. Newell. Cancer Clinical Pharmacology. Page no: 66.

- 54. Clinical pharmacology and biopharmaceutics review: NDA 21-673. https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM344961.pdf.
- 55. Center for Drug Evaluation and Research, Approval Application number: 206192Orig1s000, clinical pharmacology and biopharmaceutics review(s). https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 15/206192Orig1s000ClinPharmR.pdf
- 56. Center for Drug Evaluation and Research, Approval Application number: 202570Orig1s000, clinical pharmacology and biopharmaceutics review(s). Office of clinical pharmacology genomics group review. NDA/BLA Number: 202570 https://www.accessdata.fda.gov/drugsatfda\_docs/nda/2011/202570Orig1s000ClinPharmR.pdf.
- 57. P Balasubramanian, S Desire, JC Panetta, KM Lakshmi, V Mathews, B George, A Viswabandya, M Chandy, R Krishnamoorthy and A Srivastava. Bone Marrow Transplantation (2012) 47, 1178 1185. Population pharmacokinetics of cyclophosphamide in patients with thalassemia major undergoing HSCT. https://www.nature.com/bmt/journal/v47/n9/pdf/bmt201 1254a.pdf.
- 58. G.J. Veal *et al.* / European Journal of Cancer 55 (2016) 56-64: Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4778608/pdf/main.pdf.
- 59. Center for Drug Evaluation and Research, Approval Application number: 202806Orig1s000, clinical pharmacology and biopharmaceutics review(s). https://www.accessdata.fda.gov/drugsatfda\_docs/nda/2013/202806Orig1s000ClinPharmR.pdf.
- 60. Center for Drug Evaluation and Research, Approval Application number: 761036Orig1s000, clinical pharmacology and biopharmaceutics review(s). https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 15/761036Orig1s000ClinPharmR.pdf.
- 61. Pavan Pradeep /J Global Trends Pharm Sci, 2016; 7(3): 3367 3373. Bioequivalence, safety and tolerability of dasatinib tablets 140 mg in healthy adult volunteers under fasting conditions. https://www.jgtps.com/admin/uploads/5W0mLw.pdf.
- 62. N. Rayad, N. Gharavi, J. He, F. Trabelsi. BioPharma Services Inc. Opportunities and Challenges in Clinical Studies of Generic Anticancer Tyrosine Kinase Inhibitors. http://abstracts.aaps.org/Verify/AAPS2017/PosterSubmissions/T2069.pdf.
- 63. Center for Drug Evaluation and Research, Approval Application number: 21-790, clinical pharmacology and biopharmaceutics review(s). https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 06/021790s000 Dacogen BioPharmR.pdf.
- 64. Assessment report, Dacogen. International non-proprietary name: decitabine. Procedure No. EMEA/H/C/002221. European Medicines Agency.http://www.ema.europa.eu/docs/en\_GB/docume nt\_library/EPAR\_\_Public\_assessment\_report/human/002221/WC5001335 71.pdf.

- 65. Center for Drug Evaluation and Research, Approval Application number: 208114Orig1s000, clinical pharmacology and biopharmaceutics review(s). https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 16/208114Orig1s000ClinPharmR.pdf.
- 66. Assessment report, Defitelio. International non-Defibrotide. name: Procedure proprietary No. EMEA/H/C/002393. 25 July 2013. EMA/CHMP/824715/2012. Committee for Medicinal for Human Use (CHMP).http://www.ema.europa.eu/docs/en GB/docum ent library/EPAR -Public assessment report/human/002393/WC5001531 52.pdf.
- 67. Drug Design, Development and Therapy 2016:10 2631-2641. Pharmacokinetic profile of defibrotide in patients with renal impairment.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993270/pdf/dddt-10-2631.pdf.
- 68. Center for Drug Evaluation and Research, Approval Application number: 22-201, clinical pharmacology and biopharmaceutics review(s). https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 08/022201s000 ClinPharmR.pdf.
- 69. Center for Drug Evaluation and Research, Approval Application number: 125320, clinical pharmacology and biopharmaceutics review(s). https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 10/125320s000ClinPharmR.pdf.
- 70. Assessment report. Neofordex. International non-proprietary name: dexamethasone. Procedure No.: EMEA/H/C/002418/0000. 24 July 2014. EMA/CHMP/673863/2014. Committee for Medicinal Products for Human Use (CHMP). http://www.ema.europa.eu/docs/en\_GB/document\_librar y/Application\_withdrawal\_assessment\_report/human/00 2418/WC500177562.pdf
- 71. Scientific Discussion. Savene, INN-dexrazoxane European Medicines Agency. http://www.ema.europa.eu/docs/en\_GB/document\_librar y/EPAR\_-\_Scientific\_Discussion/human/ 000682/WC500049099.pdf
- 72. Center for Drug Evaluation and Research, Approval Application number: 125516Orig1s000, clinical pharmacology and biopharmaceutics review(s). https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 15/125516Orig1s000ClinPharmR.pdf.
- 73. Ahmad *et al.*, J Nanomed Nanotechnol 2015, 6:3. Development of Aqueous Based Formulation of Docetaxel: Safety and Pharmacokinetics in Patients with Advanced Solid Tumors. http://dx.doi.org/10.4172/2157-7439.1000295.
- 74. Center for Drug Evaluation and Research, Approval Application number: 761069Orig1s000, clinical pharmacology and biopharmaceutics review(s). https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 17/761069Orig1s000ClinPharmR.pdf.
- 75. Center for Drug Evaluation and Research, Approval Application number: NDA 22-291, clinical pharmacology and biopharmaceutics review(s).

- https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 08/022291s000 ClinPharmR P1.pdf.
- 76. Center for Drug Evaluation and Research, Approval Application number: 203415Orig1s000, clinical pharmacology and biopharmaceutics review(s). https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 08/022291s000 ClinPharmR P1.pdf.
- 77. Ralph, L. D., Thomson, A. H., Dobbs, N. A. and Twelves, C. (2004), Maximum a posteriori Bayesian estimation of epirubicin clearance by limited sampling. British Journal of Clinical Pharmacology, 57: 764-772. doi:10.1111/j.1365-2125.2004.02084.x
- Center for Drug Evaluation and Research, Approval Application number: 201532, clinical pharmacology and biopharmaceutics review(s). https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 10/201532Orig1s000ClinPharmR.pdf.
- 79. Public Assessment Report, Name of the Product: Varlota 25 mg, 50 mg, 100 mg, 150 mg, Film-coated tablets (Erlotinib hydrochloride) Procedure number: HU/H/0432/001-004/DC Marketing authorisation holder: Alvogen Malta Operations (ROW) Ltd . Date: 9 February 2017. https://www.ogyei.gov.hu/kiseroirat/ph/ph 0000136085.pdf.
- 80. Assessment report, Referral under Article 30 of Directive 2001/83/EC. Vepesid and associated names. INN of the active substance: etoposide. Procedure number: EMEA/H/A-30/1425. European Medicines Agency. http://www.ema.europa.eu/docs/en\_GB/document\_librar y/Referrals document/Vepesid 30/WC500231519.pdf.
- 81. Center for Drug Evaluation and Research, Approval Application number: NDA 22-334, clinical pharmacology and biopharmaceutics review(s). https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 09/022334s000 ClinPharmR.pdf.
- 82. Center for Drug Evaluation and Research, Application number: 203985Orig1s000, clinical pharmacology and biopharmaceutics review(s). https://www.accessdata.fda.gov/drugsatfda\_docs/nda/2012/203985Orig1s000ClinPharmR.pdf.
- 83. Center for Drug Evaluation and Research, Application number: 21-560s000, clinical pharmacology and biopharmaceutics review(s). https://www.accessdata.fda.gov/drugsatfda\_docs/nda/2010/021560s000clinpharmr.pdf.
- 84. Public Assessment Report. Scientific discussion: Exemestan "Sandoz" 25 mg film-coated tablets. Exemestane. K/H/1732/001/DC. https://db.cbg-meb.nl/Pars/h104327.pdf.
- 85. Center for Drug Evaluation and Research, Application number: 125294Orig1s000, clinical pharmacology and biopharmaceutics review(s). https://www.accessdata.fda.gov/drugsatfda\_docs/nda/2012/125294Orig1s000ClinPharmR.pdf.
- 86. Center for Drug Evaluation and Research, Application number: 125553Orig1s000, clinical pharmacology and biopharmaceutics review(s). https://www.accessdata.fda.gov/drugsatfda\_docs/nda/2015/125553Orig1s000ClinPharmR.pdf.

- 87. Kinjal Sanghavi *et al.*, Population pharmacokinetics of fludarabine (F-ARA-A) in hematopoietic cell transplant (HCT) patients. https://www.pharmacy.umn.edu/sites/pharmacy.umn.edu/files/population-pharmacokinetics-of-fludarabine.pdf
- 88. S Anjum *et al.*, Pharmacokinetics of flutamide in patients with renal insufficiency; Br J Clin Pharmacol. 1999 Jan; 47(1): 43-47; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014198/pdf/bcp0047-0043.pdf
- 89. Scientific Discussion: Faslodex: EPAR Scientific Discussion, https://www.ema.europa.eu/documents/scientific-discussion/faslodex-epar-scientific-discussion en-0.pdf
- Center for Drug Evaluation and Research, Application Number: 206995Orig1s000, Clinical Pharmacology and Biopharmaceutics Review(S). https://www.accessdata. fda.gov/drugsatfda\_docs/nda/2015/206995Orig1s000Cli nPharmR.pdf
- 91. Zhang, Hong & Li, Qingmei & Zhu, Xiaoxue & Wu, Min & Li, Cuiyun & Li, Xiaojiao & Liu, Chengjiao & Shen, Zhenwei & Ding, Yanhua & Hua, Shucheng. (2018). Association of Variability and Pharmacogenomics with Bioequivalence of Gefitinib in Healthy Male Subjects. Frontiers in Pharmacology. 9. 849. 10.3389/fphar.2018.00849.
- 92. Center for Drug Evaluation and Research, Application Number: 761060Orig1s000 &761060Orig2s000, Clinical Pharmacology and Biopharmaceutics Review(S). NDA or BLA number: BLA761060 https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 15/206995Orig1s000ClinPharmR.pdf
- 93. Lammerich *et al.* Phase I, two-way, crossover study to demonstrate bioequivalence and to compare safety and tolerability of single-dose XM17 vs Gonal-f® in healthy women after follicle-stimulating hormone downregulation; Reproductive Biology and Endocrinology (2015) 13:130.https://rbej.biomedcentral.com/track/pdf/10.1186/s12958-015-0124-y
- 94. Center for Drug Evaluation and Research, Application Number: 75143, Bioequivalence Reviews. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 15/206995Orig1s000ClinPharmR.pdf
- 95. PCI-32765 (ibrutinib); Clinical Study Report PCI-32765CLL1001. http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR\_JNJ\_6051&studyid=3872&filename=CR101204 CSR.pdf
- 96. 205552 Clinical Pharmacology Review; Center for Drug Evaluation and Research; Application Number: 205552Orig2s000; Clinical Pharmacology and Biopharmaceutics Review(s). https://www.accessdata.fda.gov/drugsatfda\_docs/nda/2013/205552Orig1s000ClinPharmR.pdf
- 97. Center for Drug Evaluation and Research, Application Number: 206545Orig1s000, Clinical Pharmacology and Biopharmaceutics review(s). NDA 205-858 and NDA 206-545.
  - https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 14/206545Orig1s000ClinPharmR.pdf
- 98. Public Assessment Report, Scientific discussion, Imatinib Fair-Med 100 mg and 400 mg, film-coated tablets, (imatinib), NL/H/3008/001-002/DC, Date: 12

- November 2015. https://db.cbg-meb.nl/Pars/h114208.pdf
- 99. Public Assessment Report, Decentralized Procedure, Imatinib 100 mg and 400 mg capsules, hard (Imatinib mesylate), UK/H/5710/001-2/DC, UK licence No: PL 36390/0179-0180, Cipla (EU) Limited. http://www.mhra.gov.uk/home/groups/par/documents/w ebsiteresources/con571564.pdf
- 100.Center for Drug Evaluation and Research, Application Number: 125377orig1s000; Clinical Pharmacology and Biopharmaceutics Review(S): BLA: 125377-0. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 11/125377Orig1s000ClinPharmR.pdf
- 101.Center for Drug Evaluation and Research, Application Number: NDA: 20—571/S-008; Clinical Pharmacology and Biopharmaceutics Review(S) of a supplemental New Drug Application: https://www.accessdata.fda.gov/drugsatfda\_docs/nda/98/020571s008\_camptosar\_clinphrmr\_admindocs\_corres.p
- 102.Center for Drug Evaluation and Research, Application Number: 207793Orig1s000; Clinical Pharmacology and Biopharmaceutics Review(S): NDA: 207793. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 15/207793Orig1s000ClinPharmR.pdf
- 103.Center for Drug Evaluation and Research, Application Number: 20-265; Clinical Pharmacology and Biopharmaceutics Review(S): NDA: 20-065 https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 07/022065s000\_ClinPharmR.pdf
- 104.Center for Drug Evaluation and Research, Application Number: 22-074; Clinical Pharmacology and Biopharmaceutics Review(S): NDA: 22-074https://www.accessdata.fda.gov/drugsatfda\_docs/nda/2007/022074s000 ClinPharmR P1.pdf
- 105.Assessment report for Tyverb, International Nonproprietary Name: Lapatinib, Procedure No. EMEA/H/C/795, Doc.Ref.: EMEA/302222/2008.https://www.ema.europa.eu/documents/assessment-report/tyverb-epar-public-assessment-report\_en.pdf
- 106.Center for Drug Evaluation and Research, Application Number: 21-880; Clinical Pharmacology and Biopharmaceutics Review(S): NDA: 21-880. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 05/021880s000\_Revlimid\_BioPharmR.pdf
- 107.Center for Drug Evaluation and Research, Application Number206947Orig1s000; Clinical Pharmacology and Biopharmaceutics Review(S): NDA: 206947.https://www.accessdata.fda.gov/drugsatfda\_docs/nda/2015/206947Orig1s000ClinPharmR.pdf
- 108.Assessment report, Lenvima, International nonproprietary name: lenvatinib, Procedure No. EMEA/H/C/003727/0000, EMA/250082/2015. https://www.ema.europa.eu/documents/assessmentreport/lenvima-epar-public-assessment-report\_en.pdf
- 109.Public Assessment Report. Decentralised Procedure. Letrozole 2.5 mg film coated tablets, PL 00289/1168, UK/H/1570/01/DC, TEVA UK Limited. https://db.cbg-meb.nl/Pars/h102826.pdf

- 110.Center for Drug Evaluation and Research, Application Number 21-343; Clinical Pharmacology and Biopharmaceutics Review(S): NDA: 21-343 https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 02/21-343 Eligard biopharmr.pdf
- 111.Center for Drug Evaluation and Research, Application Number 21-778; Clinical Pharmacology and Biopharmaceutics Review(S): NDA: 21-778 https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 05/021778s000 ClinPharmR.pdf
- 112.C. E. Nath *et al.*, Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy;Br J Clin Pharmacol / 69:5 / 484-497. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC285604 9/pdf/bcp0069-0484.pdf
- 113.Center for Drug Evaluation and Research Application Number: 207155Orig1s000, 207155Orig2s000; NDA: 207155 SDN 20; EVOMELA™ (Captisol®-enabled Melphalan HCl) for Injection; Clinical Pharmacology and Biopharmaceutics Review(S).https://www.accessdata.fda.gov/drugsatfda\_d ocs/nda/2016/207155Orig1s000\_Orig2s000ClinPharmR. pdf.
- 114.CHMP assessment report, Mercaptopurine Nova Laboratories international non-proprietary name: mercaptopurine, Procedure No. EMEA/H/C/002022, EMA/CHMP/668488/2011. https://www.ema.europa.eu/documents/assessment-report/mercaptopurine-nova-laboratories-epar-public-assessment-report en.pdf
- 115.Marshall P. Goren et. al; Similar Bioavailability of Single-Dose Oral and Intravenous Mesna in the Blood and Urine of Healthy Human Subjects; Clinical Cancer Research Vol. 4, 2313-2320, October 1998.http://clincancerres.aacrjournals.org/content/clincanres/4/10/2313.full.pdf
- 116.Center for Drug Evaluation and Research Application Number:208271Orig1s000; NDA: 208-271; RELISTOR® Tablets;Methylnaltrexone Bromide; Clinical Pharmacology and Biopharmaceutics Review(S).https://www.accessdata.fda.gov/drugsatfda\_d ocs/nda/2016/208271Orig1s000ClinpharmR.pdf
- 117.Center for Drug Evaluation and Research Application Number: 21-964; RELISTOR® (methylnaltrexone bromide) subcutaneous injection; Clinical Pharmacology and Biopharmaceutics Review(S).https://www.accessdata.fda.gov/drugsatfda\_d ocs/nda/2008/021964s000\_ClinPharmR.pdf
- 118.Center for Drug Evaluation and Research Application Number207997Orig1s000, 207997Orig2s000; RYDAPT® (midostaurin) capsules; Clinical Pharmacology and Biopharmaceutics Review(S).https://www.accessdata.fda.gov/drugsatfda\_d ocs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf
- 119.Center for Drug Evaluation and Research Application Number 125547Orig1s000; BLA: 125547/0; PORTRAZZA (necitumumab) intravenous injection; Clinical Pharmacology and Biopharmaceutics Review(S).

- https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 15/125547Orig1s000ClinPharmR.pdf.
- 120.Center for Drug Evaluation and Research Application Number:21-877; NDA: 21-877; ARRANON® (nelarabine) intravenous Injection; Clinical Pharmacology and Biopharmaceutics Review(S). https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 05/021877\_s000\_Arranon\_BioPharmr.pdf
- 121. Center for Drug Evaluation and Research Application Number:205718; Orig1s000; NDA: 205-718; AKYNZEO® (netupitant and palonosetron) capsules; Pharmacology Biopharmaceutics Clinical and Clinical Review(S). Office Pharmacology of Review PART2; https://www.accessdata.fda.gov/drugsatfda docs/nda/20 14/205718Orig1s000ClinPharmR.pdf
- 122.Center for Drug Evaluation and Research Application Number:20-068; NDA: 20068; TASIGNA® (nilotinib) capsules; Clinical Pharmacology and Biopharmaceutics Review(S). Office of Clinical Pharmacology Review. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 07/022068s000\_ClinPharmR.pdf
- 123. Center for Drug Evaluation and Research Application Number:208447Orig1s000; 208447; NDA: Zejula<sup>TM</sup>(Niraparib) capsules; Multi-discipline review; Executive Summary; Nonclinical Pharmacology/Toxicology Clinical Pharmacology Statistical Clinical Evaluation. and https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 17/208447Orig1s000MultidisciplineR.pdf
- 124.Center for Drug Evaluation and Research Application Number:125554Orig1s000; BLA:125554; Opdivo (nivolumab) 40 mg/4 mL (10 mg/mL) & 100 mg/10 mL (10 mg/mL)in a single-use vial; Clinical pharmacology and Biopharmaceutics review(s): Clinical Pharmacology BLA Review. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 14/125554Orig1s000ClinPharmR.pdf
- 125.Center for Drug Evaluation and Research Application Number:125486Orig1s000; BLA:125486; Gazyva (obinutuzumab); Clinical pharmacology and Biopharmaceutics review(s): Clinical Pharmacology Secondary Review. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 13/125486Orig1s000ClinPharmR.pdf
- 126.Center for Drug Evaluation and Research Application Number:125326; BLA:125326; Arzerra® (ofatumumab) injection; Clinical pharmacology and Biopharmaceutics review(s):
  - https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 09/125326s000 ClinPharmR.pdf
- 127.Center for Drug Evaluation and Research Application Number:206162Orig1s000; NDA:206162; Lynparza TM (Olaparib) 50 mg Capsules; Clinical pharmacology and Biopharmaceutics review(s): Clinical Pharmacology Review.
  - https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 14/206162Orig1s000ClinPharmR.pdf
- 128.CHMP assessment report on extension of marketing, authorisation grouped with a variation, Lynparza, International non-proprietary name: olaparib, Procedure

- No. EMEA/H/C/003726/X/0016/G. https://www.ema.europa.eu/documents/variation-report/lynparza-h-c-3726-x-0016-g-epar-assessment-report-extension en.pdf
- 129.Center for Drug Evaluation and Research; Application Number: 761038Orig1s000; Multi-Discipline Review; Summary / Clinical / Non-Clinical; BLA 761038 Multi-disciplinary Review and Evaluation LARTRUVO (Olaratumab).https://www.accessdata.fda.gov/drugsatfda docs/nda/2016/761038Orig1s000MultiDisciplineR.pdf
- 130. Center for Drug Evaluation and Research; Application Number: 203585Orig1s000; Clinical Pharmacology and Biopharmaceutics Review(S); Office of clinical pharmacology: Pharmacometric review; NDA: 203585. Omacetaxine mepesuccinate 3.5 mg Lyophilized Powder in a Single-Use Vial. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 12/203585Orig1s000ClinPharmR.pdf.
- 131.Center for Drug Evaluation and Research; Application Number: 208065Orig1s000; Clinical Pharmacology and Biopharmaceutics Review(S); Clinical Pharmacology NDA Review; NDA: 208,065. Tagrisso® [Osimertinib (AZD9291)] 40 mg and 80 mg Tablets. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 15/208065Orig1s000ClinPharmR.pdf
- 132.Li Q, Zhang H, Zhu X, Liu C, Wu M, Li C, Li X, Gao L and Ding Y (2018) Tolerance, Variability and Pharmacokinetics of Albumin-Bound Paclitaxel in Chinese Breast Cancer Patients. Front. Pharmacol. 9:1372. doi: 10.3389/fphar.2018.01372. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC628426 0/pdf/fphar-09-01372.pdf
- 133.Center for Drug Evaluation and Research; Application Number: 207103Orig1s000; Clinical Pharmacology and Biopharmaceutics Review(S); Clinical Pharmacology Review; FDA: 20-7103 (IND 69,324). Ibrance<sup>TM</sup> [Palbociclib (PD-0332991 or PF-00080665)] 75, 100, 125 mg capsules. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 15/207103Orig1s000ClinPharmR.pdf
- 134.Center for Drug Evaluation and Research; Approval Package For: Application Number: BLA 125103/0; Clinical Pharmacology and Biopharmaceutics Review; Kepivance<sup>TM</sup> (palifermin) human keratinocyte growth factor (KGF) rHuKGF. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 04/125103s000 Kepivance biopharmr.PDF
- 135.Center for Drug Evaluation and Research; Approval Package For: Application Number: NDA: 21-372; Clinical Pharmacology and Biopharmaceutics Review; Aloxi (palonosetron hydrochloride), 0.25 mg (free base) in 5 mL. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 03/21-372\_Alox\_BioPharmr.pdf.
- 136.Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research; Application Number: 125147/0; Clinical Pharmacology and Biopharmaceutics Review(s); Clinical Pharmacology Review: Vectibix<sup>TM</sup> (panitumumab); BB-IND 8382. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 06/125147s0000\_ClinPharmR.pdf.

- 137.Center for Drug Evaluation and Research; Application Number: 205353Orig1s000; Clinical Pharmacology and Biopharmaceutics Review(s); Office of Clinical Pharmacology Review addendum: NDA: 205353;FARYDAK® (panobinostat) capsules. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 15/205353Orig1s000ClinPharmR.pdf.
- 138.de Wit, Djoeke & Erp, Nielka & Hartigh, Jan & Wolterbeek, Ron & den Hollander-van Deursen, Margret & Labots, Mariette & Guchelaar, Henk-Jan & M. Verheul, Henk & Gelderblom, Hans. (2014). Therapeutic Drug Monitoring to Individualize the Dosing of Pazopanib: A Pharmacokinetic Feasibility Study. Therapeutic drug monitoring. 37. 10.1097/FTD.00000000000000141.
- 139.Center for Drug Evaluation and Research; Application Number: 22-465; Clinical Pharmacology and Biopharmaceutics Review(s); Office of Clinical Pharmacology Review: NDA: 22-465; VOTRIENT TM [Pazopanib (GW786034)]200 and 400 mg tablets. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 09/022465s000 ClinPharmR.pdf.
- 140.Remy B. Verheijen, Jos H. Beijnen, Jan H. M. Schellens, Alwin D. R. Huitema, Neeltje Steeghs. (2017); Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib:Towards Optimized Dosing: Clinical Pharmacokinet:DOI 10.1007/s40262-017-0510
  - zhttps://core.ac.uk/download/pdf/81792733.pdf
- 141.Assessment report; Oncaspar; International nonproprietary name: pegaspargase; Procedure No. EMEA/H/C/003789/0000: Assessment Report EMA/826135/2016. https://www.ema.europa.eu/documents/assessment
  - report/oncaspar-epar-public-assessment-report en.pdf
- 142.Lamb MW & Martin NE. Weight-based versus fixed dosing of peginterferon (40kDa) alfa-2a. Annals of Pharmacotherapy 2002; 36:933-935.
- 143.R Bruno *et al.* Area-under-the-curve for peginterferon alpha-2a and peginterferon alpha-2b is not related to body weight in treatment-naive patients with chronic hepatitis C. Antiviral Therapy 10:201-205.2005 International Medical Press 1359-6535. https://www.intmedpress.com/serveFile.cfm?sUID=745 76227-034b-43fd-a970-350563ddbdbd
- 144.Center for Drug Evaluation and Research; Application Number: 125514Orig1s000; Clinical Pharmacology and Biopharmaceutics Review(s); Clinical Pharmacology BLA Review; BLA:125514; KEYTRUDA<sup>TM</sup> (Pembrolizumab) 50 mg/vial lyophilized powder in a single-use vial. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 14/125514Orig1s000ClinPharmR.pdf.
- 145.Center for Drug Evaluation and Research; Approval Package for: Application Number: 21-462; Clinical Pharmacology Biopharmaceutics Review; NDA: 21-462 Amendment; ALIMTA(pemetrexed) for injection. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 04/21-462.pdf\_Alimta\_BioPharmr\_P2.pdf.
- 146.Center for Drug Evaluation and Research; Application Number: 125409Orig1s000; Clinical Pharmacology

- Biopharmaceutics Review(s); Clinical Pharmacology Review Amendment: BLA: 125409; PERJETA<sup>TM</sup> (pertuzumab) 420 mg/14 mL concentrate in a single use vial.
- https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 12/125409Orig1s000ClinPharmR.pdf.
- 147.Center for Drug Evaluation and Research; Application Number: 22-311; Clinical Pharmacology Biopharmaceutics Review(s); Clinical Pharmacology Review: NDA: 22-311; Mozobil<sup>TM</sup> (Plerixafor) 20 mg/mL solution for injection. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 08/022311s000 ClinPharmR.pdf.
- 148.Center for Drug Evaluation and Research; Application Number: 204026Orig1s000; Clinical Pharmacology Biopharmaceutics Review(s); Clinical Pharmacology Review: NDA: 204026; Pomalyst (Pomalidomide) 1, 2, 3, and 4 mg capsules. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 13/204026Orig1s000ClinPharmR.pdf
- 149.Final CHMP assessment report; Folotyn; International non-proprietary name; pralatrexate; Procedure No. EMEA/H/C/00209; EMA/453346/2012; Committee for Medicinal Products for Human Use (CHMP);19 April 2012.
  - https://www.ema.europa.eu/documents/assessment-report/folotyn-epar-public-assessment-report\_en.pdf
- 150.Prescribing information; EVISTA (raloxifene hydrochloride) Tablet for Oral Use Initial U.S. Approval: 1997 https://www.accessdata.fda.gov/drugsatfda\_docs/label/2 018/020815s034lbl.pdf
- 151.Center for Drug Evaluation and Research; Application Number: 203085Orig1s000; Clinical Pharmacology Biopharmaceutics Review(s); Clinical Pharmacology Review: NDA: 203-085; Stivarga (Regorafenib) Filmcoated tablet, 40 mg. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 12/203085Orig1s000ClinPharmR.pdf
- 152.Center for Drug Evaluation and Research; Application Number: 209092Orig1s000; Multi-Discipline Review; Summary Review; Office Director; Cross Discipline Team Leader Review; Clinical Review; Non-Clinical Review; Statistical Review; Clinical Pharmacology Review; Memorandum;NDA #209092; KISQALI® (ribociclib);NDA/BLA Multi-disciplinary Review and Evaluation.https://www.accessdata.fda.gov/drugsatfda\_docs/nda/2017/209092Orig1s000MultidisciplineR.pdf
- 153.Assessment report; Varuby; International nonproprietary name: rolapitant; Procedure No. EMEA/H/C/004196/0000; EMA/239011/2017; 23 February 2017.https://www.ema.europa.eu/documents/assessment

-report/varuby-epar-public-assessment-report en.pdf

154.Center for Drug Evaluation and Research; Application Number: 22-393; Clinical Pharmacology Biopharmaceutics Review(s); Clinical Pharmacology Review: NDA-NME: 22-393; ISTODAX® (romidepsin) 10 mg/vial, lyophilized powder for soultion.https://www.accessdata.fda.gov/drugsatfda\_doc s/nda/2009/022393s000\_ClinPharmR.pdf

- 155.Center for Drug Evaluation and Research; Application Number: 209115orig1s000; Multi-Discipline Review; Summary / Clinical / Non-Clinical; NDA/BLA Multi-disciplinary Review and Evaluation NDA 209115; Rubraca (rucaparib) oral tablets. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 16/209115Orig1s000MultiDisciplineR.pdf
- 156.Center for Drug Evaluation and Research; Application Number: 202192Orig1s000; Clinical Pharmacology Biopharmaceutics Review(s); Office of Clinical Pharmacology Genomics group Review: NDA/BLA Number: 202192; JAKAFI<sup>TM</sup> (ruxolitinib) tablets.https://www.accessdata.fda.gov/drugsatfda\_docs/nda/2011/202192Orig1s000ClinPharmR.pdf
- 157. Center for Drug Evaluation and Research; Application Number: 125496Orig1s000; Clinical Pharmacology Biopharmaceutics Review(s); Office of Pharmacology Review: BLA Number: 125496; [Siltuximab] (CNTO 328 Sylvant® IgG)] tablets.https://www.accessdata.fda.gov/drugsatfda docs/ nda/2014/125496Orig1s000ClinPharmR.pdf
- 158.Center for Drug Evaluation and Research; Application Number: 205266Orig1s000; Clinical Pharmacology Biopharmaceutics Review(s); Office of Clinical Pharmacology: Clinical Pharmacology Review: NDA Number: 205-266; Odomzo® [Sonidegib (LDE 225)] 200 mg capsule.https://www.accessdata.fda.gov/drugsatfda\_docs/nda/2015/205266Orig1s000ClinPharmR.pdf
- 159.Center for Drug Evaluation and Research; Approval Package for: Application Number: NDA 21-923; Clinical Pharmacology Biopharmaceutics Review; Clinical Pharmacology Biopharmaceutics NDA Review: NEXAVAR® (sorafenib) tablets 200 mg.https://www.accessdata.fda.gov/drugsatfda\_docs/nda/2005/021923\_s000\_Nexavar\_BioPharmR.pdf
- 160.Center for Drug Evaluation and Research; Approval Package for: Application Number: NDA 21-938 (GIST); NDA 21-968 (MRCC); Clinical Pharmacology Biopharmaceutics Review; Clinical Pharmacology Biopharmaceutics Review: SUTENT® (sunitinib malate) capsules. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/2006/021938\_S000\_Sutent\_BioPh armR.pdf
- 161.Shi SJ *et al.* Pharmacokinetics and comparative bioavailability of two oral formulations of tamoxifen citrate in healthy male volunteers; Asian Journal of Pharmacodynamics and Pharmacokinetics 2007; 7(3):233-238.https://pdfs.semanticscholar.org/03a9/8fd7fdd1fdf0 1d1af796dde8c834adb33b1d.pdf
- 162.Jen JF(1), Cutler DL, Pai SM, Batra VK, Affrime MB, Zambas DN, Heft S, Hajian G. Population pharmacokinetics of temozolomide in cancer patients. Pharm Res. 2000 Oct;17(10):1284-9.
- 163.https://www.ncbi.nlm.nih.gov/pubmed/11145236
- 164.Public Assessment Report of the Medicines Evaluation Board in the Netherlands; Temozolomide Glenmark 5 mg, 20 mg, 100 mg, 140 mg, 180 mg and 250 mg, capsules, hard; Glenmark Pharmaceuticals s.r.o., Czech Republic; temozolomide; EU-procedure number:

- NL/H/2489/001-006/DC; Registration number in the Netherlands: RVG 110831, 110834, 110836, 110838, 110839, 110840; 31 October 2013.https://db.cbg-meb.nl/Pars/h110840.pdf
- 165.Center for Drug Evaluation and Research; Application Number: 22-088; Clinical Pharmacology Biopharmaceutics Review(s); Clinical Pharmacology Review: NDA: 22-088; TORISEL<sup>TM</sup> Kit (temsirolimus) injection 25 mg/mL.https://www.accessdata.fda.gov/drugsatfda\_docs/nda/2007/022088s000 ClinPharmR.pdf
- 166.European Medicines Agency, Evaluation of Medicines for Human Use, Doc. Ref: EMEA/176582/2008; Assessment Report Forthalidomide Pharmion; International Nonproprietary Name: THALIDOMIDE; Procedure No. EMEA/H/C/823https://www.ema.europa.eu/documents/assessment-report/thalidomide-celgene-epar-public-assessment-report en.pdf
- 167.Public Assessment Report; Scientific discussion; Thiosix 10 mg and 20 mg, tablets (6-Thioguanine); NL License RVG 114680-114681; Date: 26 May 2015; https://db.cbg-meb.nl/Pars/h114680.pdf
- 168.Center for Drug Evaluation and Research; Application Number: 208264orig1s000; Clinical Pharmacology and Biopharmaceutics review(s); Office of Clinical Pharmacology Review; NDA Number: 208264. Tepadina (Thiotepa) Lyophilized powder for Injection, 15 mg/vial and 100 mg/vial. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 17/208264Orig1s000ClinPharmR.pdf.
- 169.Center for Drug Evaluation and Research; Application Number: 20-981; Clinical Pharmacology and Biopharmaceutics review(s); Clinical Pharmacology Review; NDA: 20-981/N-000. HYCAMTIN® (topotecan) Capsules 0.25 mg 1 mg and 4mg base/vial IV injection. https://www.accessdata.fda.gov/drugsatfda docs/nda/2007/020981s000 ClinPharmR.pdf
- 170.Masahisa Sugihara et. al. Analysis of Intra- and Intersubject Variability in Oral Drug Absorption in Human Bioequivalence Studies of 113 Generic Products; Mol. Pharmaceutics, 2015, 12 (12), pp 4405-4413.
- 171.Center for Drug Evaluation and Research; Application Number: 207953Orig1s000; Clinical Pharmacology and Biopharmaceutics review(s); Clinical Pharmacology Review-Addendum; NDA: 207953. YONDELIS (trabectedin) lyophilized powder for injection 1mg single use vial for reconstitution.
  - https://www.accessdata.fda.gov/drugsatfda\_docs/label/2 015/207953s000lbl.pdf
- 172.Center for Drug Evaluation and Research; Application Number: 204114Orig1s000; Clinical Pharmacology and Biopharmaceutics review(s); NDA Clinical Pharmacology Review; NDA: 204114/0. MEKINIST [Trametinib (GSK1120212)] 0.5, 1, 2 mg tablets. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 13/204114Orig1s000ClinPharmR.pdf
- 173.Center for Drug Evaluation and Research; Application Number: 208159Orig1s000; Clinical Pharmacology and Biopharmaceutics review(s); Clinical Pharmacology

- NDA Review; NDA: 208159/SDN 3. VISTOGARD® (Uridine Triacetate) Oral granules: 10 grams of orange-flavored oral granules.https://www.accessdata.fda.gov/drugsatfda\_docs/nda/2015/208159Orig1s000ClinPharmR.pdf
- 174.Center for Drug Evaluation and Research; Application Number: 022405Orig1s000; Clinical Pharmacology and Biopharmaceutics review(s); Clinical Pharmacology Review; NDA: 22-405. CAPRELSA (Vandetanib)100 and 300 mg tablets.https://www.accessdata.fda.gov/drugsatfda\_docs/nda/2011/022405Orig1s000ClinPharmR.pdf
- 175.Center for Drug Evaluation and Research; Application Number: 202429Orig1s000; Clinical Pharmacology and Biopharmaceutics review(s); Clinical Pharmacology Review; NDA: 202-429. Zelboraf [Vemurafenib (RO5185426)]240 mg tablets.https://www.accessdata.fda.gov/drugsatfda\_docs/nda/2011/202429Orig1s000ClinPharmR.pdf
- 176.Center for Drug Evaluation and Research; Application Number: 208573Orig1s000; Clinical Pharmacology and Biopharmaceutics review(s); Office of Clinical Pharmacology Review; NDA: 208573. VENCLEXTA®(Venetoclax) Oral Tablets: 10 mg, 50 mg, 100 mg.https://www.accessdata.fda.gov/drugsatfda\_docs/nda/2016/208573Orig1s000ClinPharmR.pdf172.
- 177.Center for Drug Evaluation and Research; Application Number: 202497Orig1s000; Clinical Pharmacology and Biopharmaceutics review(s); Ondqa Biopharmaceutics Review; NDA 505 (b)(2): 202-497. MarqiboVincristine Sulfate Liposomes Injection 0.16 mg/mL. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 12/202497Orig1s000ClinPharmR.pdf
- 178.Center for Drug Evaluation and Research; Application Number: 203388Orig1s000; Clinical Pharmacology and Biopharmaceutics review(s); Office of Clinical Pharmacology Review; NDA 203-388/ SDN: 29. ERIVEDGE® (Vismodegib) 150 mg capsules. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 12/203388Orig1s000ClinPharmR.pdf
- 179.Center for Drug Evaluation and Research; Application Number: 21-991; Clinical Pharmacology and Biopharmaceutics review(s); Offi Clinical Pharmacology Review; NDA:21-991. ZOLINZA<sup>TM</sup> (vorinostat) Capsules 100 mg. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 06/021991s000 Zolinza ClinPharmR.pdf
- 180.Center for Drug Evaluation and Research; Application Number: 125418Orig1s000; Clinical Pharmacology and Biopharmaceutics review(s); Offi Clinical Pharmacology Review; BLA: 125418. ZALTRAP<sup>TM</sup> (Aflibercept) 25 mg/mL solution for IV infusion.https://www.accessdata.fda.gov/drugsatfda\_doc s/nda/2012/125418Orig1s000ClinPharmR.pdf
- 181.Kim Margolin, Michael B. Atkins, Janice P. Dutcher, *et al.*; Phase I Trial of BAY 50-4798, an Interleukin-2^ Specific Agonist in Advanced Melanoma and Renal Cancer.Clin Cancer Res 2007;13(11) June 1, 2007. https://pdfs.semanticscholar.org/eae8/b5df9b59b1d9bc4 a0cfdf0c9dd63a827b952.pdf

- 182.D. R. Mould et.al.; Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath®) in patients with chronic lymphocytic leukaemia and its link to treatment response. PopPK-PD—outcome of alemtuzumab in CLL; Br J Clin Pharmacol 64:3. 278-291
- 0651/pdf/bcp0064-0278.pdf
  183.A. M. Novakovic et. al., Simulation-based assessment of flat dose regimen of an anti-PD-L1 antibody: case study of avelumab. https://www.page-

meeting.org/pdf assets/4847-5420623-

278.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC200

- 32\_Avelumab\_PAGE\_Poster\_r6\_PRINT\_noCrops\_final .pdf.
- 184.LJC van Warmerdaml et. al., Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support; British Journal of Cancer (1996) 73, 979-984.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC207 5820/pdf/brjcancer00036-0109.pdf
- 185.M. C. Etienne at.al., Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance. Annals of Oncology 14: 643-647, 2003.https://doi.org/10.1093/annonc/mdg162.
- 186.Mina Nikanjam et.al. Enhanced Cytarabine and Daunorubicin Population Pharmacokinetics When Administered As CPX-351: A Novel Liposomal Formulation Not Requiring Dose Reduction for Mild Renal or Hepatic Dysfunction; Blood 2016 128:395.http://www.bloodjournal.org/content/128/22/39 55
- 187.Center for Drug Evaluation and Research; Application Number: 761035Orig1s000; Clinical Pharmacology and Biopharmaceutics review(s); Office of Clinical Pharmacology Review; BLA: 761035. EMPLICITI□ (elotuzumab) for intravenous injection. https://www.accessdata.fda.gov/drugsatfda\_docs/nda/20 15/761035Orig1s000ClinPharmR.pdf
- 188.E. Sawicki *et al.* Inventory of oral anticancer agents: Pharmaceutical formulation aspects with focus on the solid dispersion technique Cancer Treatment Reviews 50 (2016) 247-263. https://www.cancertreatment reviews.com/article/S0305-7372(16)30092-5/pdf
- 189.Singh BN et.al. Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy. Clin Pharmacokinet. 2004;43(15):1127-56.
- 190.Assessment Report For Mabthera (rituximab)' Procedure No.: EMEA/H/C/000165/II/0065; Evaluation of Medicines for Human Use; EMA/717652/2010.https://www.ema.europa.eu/docume nts/variation-report/mabthera-h-c-165-ii-65-eparassessment-report-variation en.pdf
- 191.Product Monograph, Pr Zoledronic Acid for Injection Concentrate4 mg/5 mL zoledronic acid (as zoledronic acid monohydrate), Part I: Health Professional Information; Summary Product Information; http://www.drreddys.com/media/654843/zoledronic-4mg-en-pristine-pm-oct-26-17.pdf

- 192.L. O'Brien *et al.*, Population pharmacokinetic metaanalysis oframucirumab in cancer patients; Br J Clin Pharmacol. 2017 Dec; 83(12): 2741-2751.https://pdfs.semanticscholar.org/3e76/485258c604 5c10b5c1a65adfe3e59af23e06.pdf
- 193. Clinical Study Report, Elitek/Fasturtec (rasburicase, SR29142), Study Identifier: NCT00230178, Study code: EFC4978.https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/clinical-study-results/EFC4978 summary.pdf.
- 194.Brekkan, A., Lopez-Lazaro, L., Yngman, G. *et al.* A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim; The AAPS Journal (2018) 20: 91. https://link.springer.com/content/pdf/10.1208%2Fs1224 8-018-0249-y.pdf.

### How to cite this article:

Someswara Rao. K *et al.*, 2019, Intra/Inter Subject Variability of Various Anti-Cancer Drugs. *Int J Recent Sci Res.* 10(01), pp. 30218-30233. DOI: http://dx.doi.org/10.24327/ijrsr.2019.1001.3012

\*\*\*\*\*